Your session is about to expire
← Back to Search
Venetoclax + Chemotherapy for Acute Lymphoblastic Leukemia
Study Summary
This trial is testing whether combining venetoclax with standard chemotherapy drugs is safe and effective in treating newly diagnosed acute lymphoblastic leukemia (ALL) in adults.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 3 trial • 389 Patients • NCT02005471Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am able to get out of my bed or chair and move around.I am between 18 and 60 years old.I have ALL with CNS involvement and can get additional treatments for it.I don't have any active cancer needing treatment, except for minor skin cancers or cancers I've been free of for 5 years.My liver is functioning well, with specific blood test levels within acceptable ranges.I have ALL with CNS involvement and can get additional treatments for it.My kidneys are working well.I can take care of myself and am up and about more than half of my waking hours.I have been newly diagnosed with a type of leukemia that is not associated with the Philadelphia chromosome.My lymphoma does not affect my bone marrow.I have been newly diagnosed with a type of leukemia that is not associated with the Philadelphia chromosome.My liver is functioning well, with normal bilirubin and enzyme levels.I haven't had a heart attack, stroke, or severe heart issues in the last 6 months.I do not have HIV, hepatitis B, or hepatitis C.My condition is either CML in lymphoid blast crisis, Burkitt's lymphoma, or MPAL.I have had treatments for ALL, but only corticosteroids, hydroxyurea, or one dose of vincristine.I haven't taken strong or moderate CYP3A inducers in the last week.I am not pregnant or breastfeeding and will use birth control during and for 1 year after the study.I am between 18 and 60 years old.My kidneys are working well, with a creatinine clearance rate of 60 ml/min or more.My lymphoma does not affect my bone marrow.
- Group 1: Venetoclax in Combination With Chemotherapy
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What demographic is ideal for participating in this investigation?
"This clinical trial is accepting 12 individuals, between the ages of 18 and 60 with l1 acute lymphocytic leukemia. To be considered eligible for this study, participants must also satisfy these conditions: having T- or B-cell lymphoblastic lymphoma without bone marrow involvement; obtaining a performance status on ECOG scale from 0 to 2; showcasing sufficient renal function as attested by a creatinine clearance rate that surpasses 60 ml/min.; being newly diagnosed with Philadelphia chromosome (Ph) negative ALL; displaying adequate hepatic functioning as indicated by total bilirubin lower than 2.0 mg/dl (unless due to"
Is this research endeavor open to those above the age of seventy?
"Participants aged between 18 and 60 are eligible for this clinical study. Alternatively, there exist 465 trials exclusively for minors and 1188 specifically designed to treat seniors."
How many individuals are currently being accepted for enrollment in this research program?
"Affirmative. According to the clinicaltrials.gov database, this trial is presently open for participants and was first posted on June 16th 2022 before being revised a day later. A total of 12 patients must be recruited from one medical center."
Are there any openings available in this medical experiment for participants?
"According to clinicaltrials.gov, the enrolment process of this study is still ongoing; it was first made available on June 16th 2022 and has since been modified on the following day."
Share this study with friends
Copy Link
Messenger